Common Contracts
9 similar Underwriting Agreement contracts by Dyax Corp, BCD Semiconductor Manufacturing LTD, Chelsea Therapeutics International, Ltd., others
4,444,444 Shares CorMedix Inc. Common Stock ($0.001 par value) UNDERWRITING AGREEMENTUnderwriting Agreement • July 29th, 2020 • CorMedix Inc. • Pharmaceutical preparations • New York
CorMedix Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as the representatives (the “Representatives”) an aggregate of 4,444,444 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 666,666 additional shares of the Company’s Common Stock (the “Option Shares” and, together with the Firm Shares, the “Securities”).
Shares EURONAV NV Ordinary Shares (No Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • January 15th, 2015 • Euronav NV • Deep sea foreign transportation of freight • New York
Euronav NV, a Belgian limited liability company (naamloze vennootschap) (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom Deutsche Bank Securities Inc., Citigroup Global Markets Inc., J.P. Morgan
6,666,667 Shares Chelsea Therapeutics International, Ltd. Common Stock ($0.0001 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • November 15th, 2013 • Chelsea Therapeutics International, Ltd. • Biological products, (no disgnostic substances) • New York
Chelsea Therapeutics International, Ltd., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representative (the “Representative” or “you”) an aggregate of 6,666,667 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 1,000,000 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below. The Firm Shares and the Option Shares (to the extent the aforementioned option is exercised) are herein collectively called the “Shares.”
Shares Ocean Rig UDW Inc. Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • April 9th, 2012 • Ocean Rig UDW Inc. • Drilling oil & gas wells • New York
Ocean Rig UDW Inc., a Marshall Islands corporation (the “Company”) and DryShips Inc., a Marshall Islands corporation (the “Selling Shareholder”), confirm their respective agreements with you and each of the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (in such capacity, “you” or the “Representatives”), with respect to (i) the sale by the Selling Shareholder and the purchase by the Underwriters of an aggregate of shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”) and (ii) the grant by the Selling Shareholder to the Underwriters of the option, as described in Section 2(b) hereof, to purchase up to additional shares of the Company’s Common Stock (the “Option Shares”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I.
22,222,223 Shares INSPIRE PHARMACEUTICALS, INC. Common Stock ($0.001 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • August 10th, 2009 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • New York
7,425,743 Shares Dyax Corp. Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • June 25th, 2009 • Dyax Corp • Services-commercial physical & biological research • New York
Dyax Corp., a Delaware corporation (the “Company”), proposes to sell to Deutsche Bank Securities Inc. (the “Underwriter”) an aggregate of 7,425,743 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value (the “Common Stock”). The Company also proposes to sell at the Underwriter’s option an aggregate of up to 1,113,862 additional shares of Common Stock (the “Option Shares”) as set forth below.
6,000,000] American Depositary Shares BCD Semiconductor Manufacturing Limited Representing [30,000,000] Ordinary Shares (Par value US$0.001 per ordinary share) UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2008 • BCD Semiconductor Manufacturing LTD • Semiconductors & related devices • New York
The ADSs purchased by the Underwriters under this Agreement will be evidenced by American depositary receipts (“ADRs”) to be issued pursuant to a Deposit Agreement, dated as of __, 2008 (the “Deposit Agreement”), to be entered into among the Company, Deutsche Bank Trust Company Americas, as depositary (the “Depositary”), and the holders from time to time of the ADRs.
5,500,000 Shares Dyax Corp. Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • March 10th, 2006 • Dyax Corp • Services-commercial physical & biological research • New York
Dyax Corp., a Delaware corporation (the “Company”), proposes to sell to Deutsche Bank Securities Inc. (the “Underwriter”) an aggregate of 5,500,000 shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value (the “Common Stock”). The Company also proposes to sell at the Underwriter’s option an aggregate of up to 825,000 additional shares of the Company’s Common Stock (the “Option Shares”), as set forth below.
UNDERWRITING AGREEMENTUnderwriting Agreement • January 19th, 2006 • Macerich Co • Real estate investment trusts • New York
The Macerich Company, a Maryland corporation (the “Company”), proposes to sell to Deutsche Bank Securities Inc. and J.P. Morgan Securities Inc. (together, the “Underwriters”) an aggregate of 9,523,810 shares (the “Firm Shares”) of the Company’s common stock, $.01 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 1,428,571 additional shares of the Common Stock (the “Option Shares”), as set forth below. The Firm Shares and the Option Shares (to the extent the aforementioned option is exercised) are herein collectively called the “Shares.”
